Recent

% | $
Quotes you view appear here for quick access.

Talon Therapeutics, Inc. Message Board

  • royaltycruises royaltycruises Jul 25, 2012 8:44 PM Flag

    (TLON) Strong Pipeline!

    Talon Therapeutics, Inc. (TLON)
    1.68 0.15 (9.80%) 3:59PM EDT

    Trading 4 X the daily average volume today!

    (FDA) approval coming in less than 18 days for their lead drug !

    Strong pipeline!

    Short term price target is $4.50

    Marqibo® (vincristine sulfate liposome injection, OPTISOME™)
    A Novel Targeted Nanoparticle-encapsulated Anti-Cancer Compound currently for Acute Lymphoblastic Leukemia (ALL) and Melanoma. Marqibo® has a robust safety database (over 600 patients) and has been extensively evaluated in lymphoid blood cancers such as non-Hodgkin’s lymphoma (NHL) and ALL. Talon has ongoing (or planned) clinical trials which may enable an accelerated approval in 2 indications. Future clinical trial development possible in multiple indications including NHL and melanoma.
    More Details »

    Alocrest™ (vinorelbine liposomes injection, OPTISOME™)
    A Novel Targeted Anti-Cancer Compound for Breast and Lung Cancer. Alocrest™ has completed a Phase I dose-escalation trial demonstrating promising anti-cancer activity as well as acceptable and predictable toxicity. More Details »

    Brakiva™ (topotecan liposomes injection, OPTISOME™)
    A Novel Targeted Anti-Cancer Compound for Small-Cell Lung Cancer and Ovarian Cancer. Preclinical data demonstrate the value of Brakiva™ over conventional topotecan. More Details »

    Menadione Topical Lotion - A Topical Compound for Skin Rash Associated with EGFR Inhibitors. Treatment with EGFR inhibitors such as Tarceva®, Erbitux® and Vectibix® are associated with an acne-form rash involving the face, neck and upper torso in approximately 75% patients. 50% of patients who manifest skin toxicity experience significant discomfort. This results in drug discontinuation or dose reduction in at least 10% and up to 30% of all subjects. Drug delivery is targeted to the normal location of the EGFR-containing skin cells at the dermal/epidermal junction without interfering with EGFR inhibition systemically at the level of the tumor.

    SortNewest  |  Oldest  |  Most Replied Expand all replies